Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has recently been accepted by the State Drug Administration. The acceptance number is CYHS2660549, and the registration and marketing process has entered the review stage. As of the announcement disclosure date, the project has invested a total of about 5.4592 million yuan in R&D expenses. This declaration uses a full chemical synthesis route, which is completely different from the production process of huxerzine A API with the original registration number Y20190005686.

Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has recently been accepted by the State Drug Administration. The acceptance number is CYHS2660549, and the registration and marketing process has entered the review stage. As of the announcement disclosure date, the project has invested a total of about 5.4592 million yuan in R&D expenses. This declaration uses a full chemical synthesis route, which is completely different from the production process of huxerzine A API with the original registration number Y20190005686.